Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced it will report its 2024 second quarter financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. The company will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss the results and provide a business update. Interested parties can access the webcast via the Investors section of Jazz Pharmaceuticals' website.
Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, with a diverse portfolio including therapies for sleep disorders, epilepsy, and cancer. The company is headquartered in Dublin, Ireland, with operations in multiple countries.
- None.
- None.
Audio webcast/conference call:
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 9124647
Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2024-second-quarter-financial-results-on-july-31-2024-302198485.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When will Jazz Pharmaceuticals (JAZZ) report its Q2 2024 financial results?
How can investors access Jazz Pharmaceuticals' (JAZZ) Q2 2024 earnings webcast?
What time is Jazz Pharmaceuticals' (JAZZ) Q2 2024 earnings call scheduled for?